Back to list

Osage Partners

Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.

Robert Adelson

Managing Partner

Anurag Agarwal

Principal Life Science

Natasha Azar

VP of Investor Relations and Marketing University Relations

Louis Berneman

Founding Partner

Matthew Cohen

Partner Life Science

KC

Kevin C. Coleman

VP of Acquisitions

Sean Dowling

Partner

David Drahms

Partner

Claudia Dunnous

CFO Finance

Emily Foote

Principal

Beth Grafstrom

VP of Finance Finance

JG

Jon Gulardo

Associate

Margalit Haber

Associate Life Science

WH

William Harrington

Managing Partner

Bill Harrington

Managing Partner Life Science

Nate Lentz

Managing Partner

NV

Nathanael V. Lentz

Managing Partner and Partner

Kirsten Leute

Partner University Relations

CL

Collin Luft

Associate

Michael Phelan

Venture Partner

Ajay Rayasam

Associate Technology

Marc Singer

Managing Partner Technology

Manny Stockman

Principal Technology

313 past transactions

Effector Therapeutics

Series B in 2015
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Algorithmia, Inc.

Series B in 2019
Algorithmia, Inc. provides the infrastructure that enables algorithm developers to explore, create, and share algorithms as Web services. The company helps its clients deploy models into production by creating a versioned, scalable API (application program interface) endpoint any application or model can call. The company's product helps clients work on Tensorflow, PyTorch, Scikit-learn, and MXNet. Algorithmia, Inc. was founded in 2013 and is based in Seattle, Washington.

Menlo Security, Inc.

Series E in 2020
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.
Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals and Nutritionals. - The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). - The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Censys, Inc.

Series A in 2020
Censys, Inc. provides internet scanning and asset identification solutions. It offers Censys, an internet device search engine for finding internet devices, such as computers, servers, and smart devices that hosts the data. The company’s Censys is used for attack surface management, search and API, home network risk identifier, and bulk internet data. Its solution is used in various use cases, such as discovering unknown assets, monitoring remote workforce, and identifying threat actors. The company was founded in 2017 and is based in Ann Arbor, Michigan.

SiFive, Inc.

Series E in 2020
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and more affordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small.

Vor Biopharma

Series B in 2020
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Palladio Biosciences, Inc., a biotechnology company, that develops transformative medicines for orphan diseases of the kidney. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. Palladio Biosciences, Inc. was founded in 2015 and is based in Horsham, Pennsylvania.

Ribon Therapeutics

Series A in 2016
Ribon Therapeutics, Inc. operates as biotechnology company, which develops therapeutics novel enzymes for cancer medicines. The company was incorporated in 2015 and is based in Lexington, Massachusetts.

Pliant.io

Series A in 2021
Pliant.io, Inc. develops an infrastructure automation platform that enables ITOps to plan, build, and deploy API-level automations. It offers Pliant, an orchestration, automation, and response (OAR) platform that provides endpoints, graphical representations, and uniform building blocks that enables developers to automate complex cross-domain processes. The company’s solution is used various use cases, such as virtual machine provisioning, server audit and remediation, ITSM orchestration, hybrid network configuration, and application delivery and security. The company was founded in 2017 and is based in Boston, Massachusetts.

E-scape Bio

Series C in 2020
E-Scape Bio, Inc., a biopharmaceutical company, discovers and develops small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. Its programs improve the lives of patients suffering from Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

PsiKick

Series B in 2019
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-power circuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams. The company was founded on 2012 and is based in Santa Clara, California.

boodleAI

Seed Round in 2020
boodleAI delivers people-based predictive analytics using the organization's data, third party data, and AI/machine learning to enable: (1) nonprofits to acquire, grow, and retain donors (boodle.ai); (2) veteran political candidates to raise contributions (adjutant.ai); and (3) B2C commercial companies to acquire, grow, and retain customers (guidon.ai).

Glyphic Biotechnologies

Seed Round in 2021

InstaMed

Venture Round in 2009
InstaMed powers a better healthcare payment experience on one platform that connects consumers, providers, and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, moving money, and healthcare data seamlessly, and improving consumer satisfaction. It was formed in 2004 and headquartered in Philadelphia, Pennsylvania.

ANRA Technologies, LLC

Venture Round in 2021
Developer of a cloud-based drone operational platform designed to support commercial entities for launching and managing commercial drone operations. The company's platform offers flight planning, airspace management, data analytics, compliance, drone management, resource management and maintenance information in a singular platform, enabling drone operators and service providers to have access to the command and control for one or multiple unmanned aerial vehicle (UAV) operations at any given time.

Trinsic

Seed Round in 2022

Automated Insights

Series B in 2014
Automated Insights is a provider of content automation services. It is the creator of Wordsmith, the world’s first public natural language generation template engine. Wordsmith allows users to generate human-sounding narratives from data, making it easy to produce millions of personalized reports, articles, and narratives in the time it takes to write just one. The Wordsmith platform helps companies in data-driven industries, including financial services, e-commerce, real estate, business intelligence, media, and many others, achieve content scale, efficiency, and personalization. More than 200 customers, including Allstate, The Associated Press, Edmunds.com, the Orlando Magic, and Yahoo! use Wordsmith to generate more than 1.5 billion pieces of content per year.

Menlo Security, Inc.

Series E in 2020
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

Q32 Bio

Series B in 2020
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

ReCode Therapeutics

Series A in 2020
Recode Therapeutics, Inc., a biopharmaceutical company, develops precision medicines for pulmonary diseases. Its pipeline includes programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The company’s non-viral lipid nanoparticle platform enables the delivery of various payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. Recode Therapeutics, Inc. was founded in 2015 and is based in Menlo Park, California.

RackWare Incorporated

Series A in 2014
RackWare offers mobility to the data center to leverage private, public, or hybrid cloud environments. RackWare enables seamless transfer of those images to any other data center (physical or cloud) and deployment on any physical, virtual, or cloud platform. It was founded in 2009 and headquartered in Fremont, California.

AppBus, Inc.

Pre Seed Round in 2015
AppBus provides a digital business platform that integrates, automates and secures enterprise application delivery to any device on any network. With AppBus, acclimating to change is simple, we leverage the capabilities of the enterprise, enable transparency for automation and accelerate the delivery of optimal experiences. Our platform ensures innovation and time to value throughout the enterprise ecosystem with employees, customers, and partners.

DeepHow

Seed Round in 2021
DeepHow develops an AI-powered learning platform for manufacturing, service, and repair. Wei-Liang Kao, Patrik Matos da Silva, and Samuel Zheng founded it in 2018, with its headquarters in New York City.

Brimstone Energy

Series A in 2022
Brimstone Energy is a hardware cleantech startup that aims to reduce CO2 emissions through innovative technologies.

Hyalex Orthopaedics

Series A in 2017
Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

DrayNow

Series A in 2019
DrayNow is the first real-time marketplace for matching intermodal freight and carriers. The company's intermodal marketplace uses technology to connect intermediaries to more carriers on short notice, maintain visibility of the shipment's location and status at all times, and helps truckers to compare rates, view load details, and select available loads in their area in real-time, enabling companies in the intermodal industry to operate with increased efficiency in order to maintain optimal levels of capacity, service, visibility, and profitability.

CIPIO.ai

Seed Round in 2021
CIPIO Inc. develops a customer intelligence platform for B2C businesses. It offers CIPIO that democratizes hyper-personalized predictions and recommendations throughout the customer journey. The company’s CIPIO that operates as a domain-infused intelligent assistant to identify the right customers, products, channels, and offers to improve engagement and wallet share across the customer journey. The company was incorporated in 2019 and is based in Fairfax, Virginia with additional offices in Redwood City, California; and Bengaluru and Ahmedabad, India.

PsiKick

Venture Round in 2017
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-power circuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams. The company was founded on 2012 and is based in Santa Clara, California.

PMV Pharmaceutcals

Series C in 2019
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Interius BioTherapeutics

Series A in 2021
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

Atsena Therapeutics

Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

MarginEdge Co.

Series A in 2019
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.

ANRA Technologies, LLC

Seed Round in 2019
Developer of a cloud-based drone operational platform designed to support commercial entities for launching and managing commercial drone operations. The company's platform offers flight planning, airspace management, data analytics, compliance, drone management, resource management and maintenance information in a singular platform, enabling drone operators and service providers to have access to the command and control for one or multiple unmanned aerial vehicle (UAV) operations at any given time.

SiFive, Inc.

Series E in 2020
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and more affordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small.

RackWare Incorporated

Series B in 2016
RackWare offers mobility to the data center to leverage private, public, or hybrid cloud environments. RackWare enables seamless transfer of those images to any other data center (physical or cloud) and deployment on any physical, virtual, or cloud platform. It was founded in 2009 and headquartered in Fremont, California.

DeepSurface Security, Inc

Seed Round in 2022
DeepSurface Security (www.deepsurface.com) is the first automated Predictive Vulnerability Management suite of tools that helps cybersecurity teams automate the process of analyzing and prioritizing vulnerabilities by risk contribution on enterprise networks. Created by a veteran cybersecurity team, DeepSurface Security is trusted by enterprise companies to identify, prioritize, and research vulnerabilities in their networks. Headquartered in Portland, Oregon, DeepSurface is a privately held company funded by Cascade Seed Fund, SeaChange Fund, and Voyager Capital. To learn more visit www.deepsurface.com.

Spero Therapeutics

Series C in 2017
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.

TimelinePI, Inc.

Venture Round in 2017
TimelinePI, Inc. develops new process and timeline visualization software to detect and present detailed views of business processes. The company provides solutions, including business process management, employee journey mapping, IT service management, procurement, and blue prism. It offers its services for financial services, insurance, and healthcare. The company was founded in 2015 and is based in Springfield, Pennsylvania. As of August 5, 2019, TimelinePI, Inc. operates as a subsidiary of ABBYY USA Software House, Inc. As of August 5, 2019, TimelinePI, Inc. operates as a subsidiary of ABBYY USA Software House, Inc.

Nikola Labs LLC

Series A in 2022
Nikola Labs LLC is a wireless power company that develops technology to convert radio frequency (RF) energy into direct current (DC) power for electronic devices. Its technology converts RF signals, such as Wi-Fi, Bluetooth, and LTE into DC power that is ideal for low-power wireless sensors. The company was founded in 2014 and is based in Columbus, Ohio.

Halfpenny Technologies

Series A in 2012
Halfpenny Technologies, Inc. develops cloud-based healthcare interoperability solutions. It provides clinical data exchange solutions, orders management and computerized provider order entry solutions, business intelligence and notification solutions, and clinical data services. The company’s cloud-based solutions offers vendor-neutral infrastructure that supports care coordination, care management, regulatory requirements, and data analysis within and between healthcare organizations. It serves health plans, accountable care organizations, hospitals, radiology centers, pharmacies, commercial laboratories, population health, care coordination vendors, and HIEs in the United States. The company was founded in 2000 and is based in Blue Bell, Pennsylvania. As of June 14, 2019, Halfpenny Technologies, Inc. operates as a subsidiary of Accumen.

Effector Therapeutics

Series C in 2017
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Elementary Robotics, Inc.

Seed Round in 2018
Elementary Robotics, Inc. manufactures robots for human assistance. It offers robots to automate QA and traceability for AI-assisted manufacturing. The company’s robots are also used to track the stages of assembly across production lines. It serves electronics, automotive, medical, and consumer packaged goods and logistics industries. The company was founded in 2017 and is based in Pasadena, California with additional offices in Mexico and Chicago.

Semantic Research Inc.

Venture Round in 2017
Semantic AI is a software company that develops enterprise intelligence solutions. They created Cortex EIP products that offer a track record of successfully fusing, analyzing, and visualizing data for critical DOD missions. Semantic AI was founded by Richard Harrison in California.

Verge Aero

Venture Round in 2017
Verge Aero (Verge) is a Philadelphia-based team of electrical, computer, software, systems, and aerospace engineers, whose mission is focused on building and deploying unmanned aerial systems (UASs), or drones, for use in the entertainment industry. Verge has designed, developed, and implemented a drone performance software capable of controlling swarms of drones and integrating into existing entertainment systems, providing dynamic interactions with audiences and actors. Near-term applications of the technology include recurring drone performances, venue installations, touring drone performance productions, and drone entertainment products.

PeopleLinx, Inc.

Series A in 2014
PeopleLinx made selling easy by integrating social into the team's sales process and metrics. PeopleLinx guides sales professionals to build relationships, attract qualified leads, and drive deals using online social networks. Their technology maps to the sales process integrated with CRM, and measures results. PeopleLinx’s customers include Fortune 500 leaders in financial services, high-tech, and professional services. It was founded by early LinkedIn employees in 2009 and is headquartered in Philadelphia, Pennsylvania.

Cleave Biosciences

Series B in 2016
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Katabat

Private Equity Round in 2020
Katabat™ enables digital transformation with complete visibility across the consumer lifecycle. Experience our unified platform that increases customer satisfaction and retention, at a lower cost. Whether you are a servicer, lender, retailer, or utility, our SaaS solutions create an outstanding on-demand experience while driving security, compliance, and revenue. Katabat was founded by financial and technology industry experts, so we fully understand your security and compliance needs. Data security is part of our culture, and you can see that in our platform’s uncompromising security standards. Katabat™ is a PCI Level 1 Service Provider and your data is encrypted using the most secure F5 firewalls. https://katabat.com/our-story/

PeopleLinx, Inc.

Series A in 2013
PeopleLinx made selling easy by integrating social into the team's sales process and metrics. PeopleLinx guides sales professionals to build relationships, attract qualified leads, and drive deals using online social networks. Their technology maps to the sales process integrated with CRM, and measures results. PeopleLinx’s customers include Fortune 500 leaders in financial services, high-tech, and professional services. It was founded by early LinkedIn employees in 2009 and is headquartered in Philadelphia, Pennsylvania.

Antiva Biosciences, Inc.

Series C in 2017
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Connected2Fiber, Inc.

Series A in 2019
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.

MicroTransponder, Inc.

Series E in 2022
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and various neurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues. Founded in 2007, MicroTransponder is headquartered in Dallas, Texas.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Modis Therapeutics

Series A in 2018
Modis Therapeutics, Inc. develops disease modifying therapies for rare genetic diseases. The company designs and develops a therapy MT1621, which restores mitochondrial DNA replication fidelity. The company was incorporated in 2016 and is based in Oakland, California. As of September 6, 2019, Modis Therapeutics, Inc. operates as a subsidiary of Zogenix, Inc..

Wylei, Inc.

Venture Round in 2017
Wylei provides adaptive content solutions to agencies and brands to increase digital messaging relevance and engagement. It uses advanced predictive algorithms to take the guesswork out of digital web, email, mobile, and video campaigns. Wylei's Adaptive Content(TM) and Predictive Intelligence, delivers emails that adapt to the specific context of open, based on where, how, and when the email is viewed.

Menlo Security, Inc.

Seed Round in 2014
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

DiCE Molecules Corp

Series C in 2021
DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Verve Motion

Series A in 2021
Verve Motion focuses on lightweight wearables that protect and power workers for a safer work experience and restful nights.

Vector Launch, Inc.

Series B in 2018
Vector was founded by several members of the original SpaceX team and is a disruptive innovator that connects space startups with affordable and frequent launch and platforms to enable space capabilities at a speed and price point never before possible. Vector has a big vision to reshape the 400 billion dollar space market by combining dedicated low-cost micro satellite launch and software defined satellites (Galactic Sky) to dramatically increase access and speed to orbit.

ExecOnline, Inc.

Series B in 2017
ExecOnline, Inc. provides a learning platform for business executives. Its Executive Engagement Platform combines enterprise reporting and assessment solutions with an engaging and interactive experience user for individual executive learners. The company also provides online business education programs to business schools and corporate sectors. ExecOnline, Inc. was incorporated in 2012 and is based in New York, New York.

Vor Biopharma

Series A in 2019
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Antiva Biosciences, Inc.

Series C in 2018
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

MC10, Inc.

Series B in 2011
MC10, Inc. develops and sells wearable medical sensors for collecting medical grade, clinical quality bio-metric, and physiological data in a clinical trial setting. The company’s products include BioStamp nPoint, which collects and processes raw data into recognizable clinical metrics including vital signs, activity and posture classification, and sleep metrics; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, a cardiac monitoring and electrocardiographs (ECG) recording solution; and BioStampMD, a wearable sensor conforming to the human body to collect objective and patient-reported subjective data. It sells its products online. The company was founded in 2008 and is based in Lexington, Massachusetts.

GoCanvas

Series C in 2014
GoCanvas is a mobile platform that makes it simple for any business to automate how work is done, replacing outdated processes and expensive paperwork. The GoCanvas App works on all smartphones and tablets, helping companies easily collect information across their organization, share it instantly with others, and gain real-time insights on their business operations. It was founded in 2008 and headquartered in Reston, Virginia.

ArsenalBio

Series A in 2019
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.

Seismos

Series A in 2015
Seismos, the K-wave Company™, is a data analytics company for production optimization providing proprietary solutions enabling real-time, underground fluid flow monitoring, inside the reservoir, during production. Monitoring fluid movement with conventional seismic technologies requires months for data acquisition and processing, disrupts production and costs millions. Seismos breaks this paradigm and solves all problems associated with conventional methods by providing real-time information, at a fraction of the cost, through its proprietary, cloud-based K-wave technology that is non-invasive to production and to surface operations.

Identropy

Series A in 2012
At Identropy, we’re OCD about making customers successful in their Identity Management initiatives. It has been our sole focus since our founding in 2006, and most of us have over 10 years of experience in this space. While we’ve had the privilege of making many clients successful, we’ve also seen firsthand how difficult these programs can be to implement and to sustain. We believe that cloud computing provides the platform that can truly revolutionize how IDM solutions are delivered and consumed, and bring to fruition the vision of better security, lowered costs, and fast time-to-value.

Strategikon Pharma, Inc.

Series A in 2021
Strategikon Pharma, Inc. designs and develops a software that synchronizes sponsor and provider outsourcing processes. It offers Clinical Maestro, a transaction room that uses collaborative technology infrastructure and standardized bid grid language to create a shared virtual transaction environment. The company's software is also used for clinical financial management, vendor performance metrics management, portfolio analytics, CRO and clinical vendor oversight, clinical outsourcing, and contract lifecycle management. In addition, it offers consulting services to newly established clinical business operations. Strategikon Pharma, Inc. was founded in 2016 and is based in San Rafael, California.

Sideris Pharmaceuticals

Series A in 2013
Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

Spero Therapeutics

Post in 2018
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.

SevOne

Series C in 2015
Provides infrastructure performance monitoring solutions for customers worldwide

Connected2Fiber, Inc.

Series B in 2021
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.

DrayNow

Series A in 2020
DrayNow is the first real-time marketplace for matching intermodal freight and carriers. The company's intermodal marketplace uses technology to connect intermediaries to more carriers on short notice, maintain visibility of the shipment's location and status at all times, and helps truckers to compare rates, view load details, and select available loads in their area in real-time, enabling companies in the intermodal industry to operate with increased efficiency in order to maintain optimal levels of capacity, service, visibility, and profitability.

PeopleLinx, Inc.

Series A in 2015
PeopleLinx made selling easy by integrating social into the team's sales process and metrics. PeopleLinx guides sales professionals to build relationships, attract qualified leads, and drive deals using online social networks. Their technology maps to the sales process integrated with CRM, and measures results. PeopleLinx’s customers include Fortune 500 leaders in financial services, high-tech, and professional services. It was founded by early LinkedIn employees in 2009 and is headquartered in Philadelphia, Pennsylvania.

Sidecar

Series C in 2017
Sidecar is an e-commerce marketing company that builds the advanced technology retailers need to optimize cross-channel online shopping campaigns. With a team of data science and e-commerce experts, our state-of-the-art machine learning engine, and a massive volume of data, Sidecar is the magic behind retail's most efficient and powerful online shopping campaigns.

Delfi Diagnostics, Inc.

Series B in 2022
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. It was founded in 2019 and is headquartered in Baltimore, Maryland.

Ceptaris Therapeutics

Series B in 2006
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Antiva Biosciences, Inc.

Series D in 2021
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Clarifai

Series A in 2015
Clarifai provides advanced image recognition systems for customers to detect near-duplicates and visual searches. Clarifai’s image recognition systems recognize various categories, objects, and tags in images, as well as find similar images. The company’s image recognition systems allow its users to find similar images in large uncategorized repositories using a combination of semantic and visual similarities. Clarifai was founded in 2013 and is headquartered in New York, United States.

Brazen Technologies, Inc.

Series C in 2019
Brazen Technologies, Inc. design and develops chat-based recruiting software. The company offers live chat, scheduled chat, chat events, and Artificial Intelligence-powered chatbots. It also provides a javascript-based career site and job requisition plugins. Brazen Technologies, Inc. was formerly known as Brazen Careerist, Inc. and change its name to Brazen Technologies, Inc. in February 2010. The company was founded in 2007 and is headquartered in Arlington, Virginia.

ANRA Technologies, LLC

Seed Round in 2021
Developer of a cloud-based drone operational platform designed to support commercial entities for launching and managing commercial drone operations. The company's platform offers flight planning, airspace management, data analytics, compliance, drone management, resource management and maintenance information in a singular platform, enabling drone operators and service providers to have access to the command and control for one or multiple unmanned aerial vehicle (UAV) operations at any given time.

Arrakis Therapeutics

Series A in 2017
Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Malbek

Series A in 2021
Malbek is an AI platform that provides enterprise contract lifecycle management from a request, redlining, signature, and commitment tracking. It provides an innovative quote and contract lifecycle management solution that is laser-focused on accelerating contract cycle time, improving efficiency, and increasing contract visibility. With user experience as simple as using an ATM, its solution provides end-users as well as application admins a simple consumer-grade user interface with all configurable, no code-customization, capabilities.

ProtonMedia

Venture Round in 2013
ProtonMedia, Inc. provides e-learning solutions. The company develops ProtoSphere, a business collaboration software that allows organizations to create a 3D environment optimized for business applications, such as e-learning and virtual meetings, as well as virtual conference events, scientific research and development, and sales and manufacturing collaborations involving rich data visualization. It serves clients in pharmaceuticals, medical devices, financial services, and technology worldwide. ProtonMedia, Inc. was founded in 1998 and is based in Lansdale, Pennsylvania.

Coho Therapeutics

Seed Round in 2021

Synthorx, Inc.

Series C in 2018
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. As of January 23, 2020, Synthorx, Inc. operates as a subsidiary of Sanofi.

Tellie

Series A in 2022

Menlo Security, Inc.

Series A in 2014
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

Transeo

Seed Round in 2021
Transeo is a cloud-based educational solution that helps students and administrators track, report, and celebrate their community service learning experiences. We make hour verification, logging, and report generation easy for students and counselors. We are helping schools and districts move away from paper-based processes so counselors can invest more quality time with the people who matter the most: students.

Frontline Selling

Venture Round in 2013

ReCode Therapeutics

Series B in 2021
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Iconic Therapeutics

Venture Round in 2018
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Guardant Health

Series A in 2014
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Fortis Therapeutics

Series A in 2016
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

ProtonMedia

Series A in 2009
ProtonMedia, Inc. provides e-learning solutions. The company develops ProtoSphere, a business collaboration software that allows organizations to create a 3D environment optimized for business applications, such as e-learning and virtual meetings, as well as virtual conference events, scientific research and development, and sales and manufacturing collaborations involving rich data visualization. It serves clients in pharmaceuticals, medical devices, financial services, and technology worldwide. ProtonMedia, Inc. was founded in 1998 and is based in Lansdale, Pennsylvania.

Circonus, Inc.

Series B in 2021
Circonus is a machine data intelligence and analytics platform for the world’s most demanding use cases. It collects, stores, manages, and analyzes IoT and IT Infrastructure data at unprecedented volume and frequency. The platform enables companies to optimize operations, gain valuable insights, and deliver user experiences with total confidence that they are getting accurate, real-time information. The company was founded in 2010 and is headquartered in Fulton, Maryland.

Arrakis Therapeutics

Series B in 2019
Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Sidecar

Series C in 2019
Sidecar is an e-commerce marketing company that builds the advanced technology retailers need to optimize cross-channel online shopping campaigns. With a team of data science and e-commerce experts, our state-of-the-art machine learning engine, and a massive volume of data, Sidecar is the magic behind retail's most efficient and powerful online shopping campaigns.

Landos Biopharma

Series B in 2019
Landos Biopharma, Inc., a biopharmaceutical company, develops treatments for autoimmune diseases. It offers oral therapeutics, including BT-11 that is a locally-acting small molecule targeting inflammatory bowel disease (IBD). BT-11 is based on a novel mechanism of action targeting the Lanthionine Synthetase C-like 2 (LANCL2) pathway in immune cells of the gut. The company was incorporated in 2017 and is based in Blacksburg, Virginia.

Wylei, Inc.

Seed Round in 2014
Wylei provides adaptive content solutions to agencies and brands to increase digital messaging relevance and engagement. It uses advanced predictive algorithms to take the guesswork out of digital web, email, mobile, and video campaigns. Wylei's Adaptive Content(TM) and Predictive Intelligence, delivers emails that adapt to the specific context of open, based on where, how, and when the email is viewed.

Blade Therapeutics, Inc.

Series B in 2016
Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. operates as biotechnology company, which develops therapeutics novel enzymes for cancer medicines. The company was incorporated in 2015 and is based in Lexington, Massachusetts.

FieldView Solutions

Series A in 2009
FieldView Solutions helps data center managers, IT and Facilities Management professionals make better use of their physical floor space, rack space, power and cooling by showing them real-time representations of all the critical systems in their data center. Their core platform, FieldView, a web-based enterprise solution, has been leveraged by many of the largest data centers in the US, Europe and Asia since 2006.
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

ExecOnline, Inc.

Series D in 2021
ExecOnline, Inc. provides a learning platform for business executives. Its Executive Engagement Platform combines enterprise reporting and assessment solutions with an engaging and interactive experience user for individual executive learners. The company also provides online business education programs to business schools and corporate sectors. ExecOnline, Inc. was incorporated in 2012 and is based in New York, New York.

Corelight, Inc.

Series D in 2021
Corelight, Inc. provides network visibility solutions for information security professionals. It offers Corelight sensors; Corelight fleet manager; software products; and solutions to secure networks for enterprises, government, and higher education sectors. The company also provides open-source Bro, an open source network analysis framework that generates actionable, real-time data for various security teams worldwide. Corelight, Inc. was founded in 2013 and is based in San Francisco, California. It has additional offices in San Francisco and Santa Clara, California; and Columbus, Ohio.

DiCE Molecules Corp

Series C in 2021
DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Hack The Box Ltd.

Series A in 2021
Hack The Box Ltd. operates an online platform to test and advance skills in penetration testing and cyber security for companies, individuals, and universities. The company was founded in 2017 and is based in Folkestone, United Kingdom.

Seismos

Venture Round in 2018
Seismos, the K-wave Company™, is a data analytics company for production optimization providing proprietary solutions enabling real-time, underground fluid flow monitoring, inside the reservoir, during production. Monitoring fluid movement with conventional seismic technologies requires months for data acquisition and processing, disrupts production and costs millions. Seismos breaks this paradigm and solves all problems associated with conventional methods by providing real-time information, at a fraction of the cost, through its proprietary, cloud-based K-wave technology that is non-invasive to production and to surface operations.

Refraction AI

Seed Round in 2021
Refraction AI, Inc., an autonomous delivery robot company, builds and deploys robotic platforms to provide goods delivery in urban areas. It offers The REV-1, a delivery robotic vehicle that picks up goods from restaurants, pharmacies, and grocery stores, and bring them directly to the customers’ house. Refraction AI, Inc. was founded in 2017 and is based in Ann Arbor, Michigan.

eGenesis

Series C in 2021
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Hyalex Orthopaedics

Series A in 2019
Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

Ostendio

Series A in 2021
Ostendio’s MyVCM™ streamlines the way companies build, manage and demonstrate their information security framework. The MyVCM platform provides an enterprise view of an organization’s cybersecurity program. MyVCM’s unique bottom-up security approach provides a workflow solution which engages every employee and manages all aspects of security and compliance which allows organizations to easily report their security posture to internal and external stake-holders. With MyVCM, customers can ensure they are secure and compliant. Ostendio is headquartered in Arlington, VA and has customers in North America, Europe, the Middle East and Australia.

Liquid Light Corporation

Series B in 2014
Liquid Light Corporation develops and licenses process technology to make chemicals from carbon dioxide (CO2). Its technology is centered on low-energy catalytic electrochemistry to convert CO2 to multi-carbon chemicals. The company is developing process for the production of ethylene glycol. Liquid Light Corporation was incorporated in 2008 and is based in Monmouth Junction, New Jersey. As of January 10, 2017, Liquid Light Corporation operates as a subsidiary of Avantium Technologies B.V..

GoCanvas

Series D in 2014
GoCanvas is a mobile platform that makes it simple for any business to automate how work is done, replacing outdated processes and expensive paperwork. The GoCanvas App works on all smartphones and tablets, helping companies easily collect information across their organization, share it instantly with others, and gain real-time insights on their business operations. It was founded in 2008 and headquartered in Reston, Virginia.

Vanqua Bio

Series B in 2021
Medallion Analytics is a web solution designed that gives control over compliance and cost across the entire origination process. Medallion closes the gap between the loan origination system and the post-closing environment. It was incorporated in 2009 and is headquartered in Pittsburgh, Pennsylvania.

MC10, Inc.

Series A in 2010
MC10, Inc. develops and sells wearable medical sensors for collecting medical grade, clinical quality bio-metric, and physiological data in a clinical trial setting. The company’s products include BioStamp nPoint, which collects and processes raw data into recognizable clinical metrics including vital signs, activity and posture classification, and sleep metrics; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, a cardiac monitoring and electrocardiographs (ECG) recording solution; and BioStampMD, a wearable sensor conforming to the human body to collect objective and patient-reported subjective data. It sells its products online. The company was founded in 2008 and is based in Lexington, Massachusetts.

Selecta Biosciences

Post in 2017
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Delfi Diagnostics, Inc.

Series A in 2021
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. It was founded in 2019 and is headquartered in Baltimore, Maryland.

Artizan Biosciences

Series A in 2019
Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

Censys, Inc.

Series A in 2020
Censys, Inc. provides internet scanning and asset identification solutions. It offers Censys, an internet device search engine for finding internet devices, such as computers, servers, and smart devices that hosts the data. The company’s Censys is used for attack surface management, search and API, home network risk identifier, and bulk internet data. Its solution is used in various use cases, such as discovering unknown assets, monitoring remote workforce, and identifying threat actors. The company was founded in 2017 and is based in Ann Arbor, Michigan.
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Connected2Fiber, Inc.

Series A in 2018
Connected2Fiber helps the network industry transact and improve its return on marketing investment with the industry’s only SaaS marketplace enablement platform that combines Account Based Marketing, Location Intelligence with predictive algorithms that learns how to improve results. The platform helps network owners and network buyers improve transparency, speed and effectiveness with information, automation and predictive algorithms. Connected2Fiber is based in Hopkinton, MA, and was founded in 2015 by Ben Edmond. The Connected World was built to provide a better way to view, share, manage, learn and engage at a location level for networks.

Luxtera

Series D in 2008
Luxtera, Inc., designs and builds front panel and embedded optical modules based on its silicon photonics technology for data centers and mobile infrastructure. Its products include faceplate pluggable optical transceivers and embedded optical transceiver. Luxtera, Inc. was founded in 2001 and is based in Carlsbad, California. As of February 6, 2019, Luxtera, Inc. operates as a subsidiary of Cisco Systems, Inc.

Fortis Therapeutics

Series A in 2021
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

SiFive, Inc.

Series C in 2018
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and more affordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small.
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

HUED

Seed Round in 2021
HUED is a platform that diversifies the patient/doctor connection by connecting patients with diverse healthcare providers.

Pneuron

Series B in 2013
Pneuron overcomes the time, cost, and complexity challenges associated with traditional enterprise development, deployment and integration approaches. Using Pneuron’s Distributed Platform, organizations can leverage existing systems and infrastructure to connect data, applications, processes, and analytics without the need of intermediary databases, associated data integration costs or system replacement. In a single non-invasive “fabric” Pneuron allows the enterprise to manage the entire business solution lifecycle from a single screen – including development, deployment, integration, resiliency, availability and performance - freeing the enterprise to focus on realizing business value. The result is unprecedented productivity, engagement of business expertise, and reduced cost of success, inspiring new waves of innovation.

BA Insight

Venture Round in 2013
BA Insight develops integrated search technologies that help organizations enhance Microsoft SharePoint® usage

CampaignerCRM

Series A in 2006
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.

MC10, Inc.

Venture Round in 2018
MC10, Inc. develops and sells wearable medical sensors for collecting medical grade, clinical quality bio-metric, and physiological data in a clinical trial setting. The company’s products include BioStamp nPoint, which collects and processes raw data into recognizable clinical metrics including vital signs, activity and posture classification, and sleep metrics; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, a cardiac monitoring and electrocardiographs (ECG) recording solution; and BioStampMD, a wearable sensor conforming to the human body to collect objective and patient-reported subjective data. It sells its products online. The company was founded in 2008 and is based in Lexington, Massachusetts.

Moda Technology Partners

Series A in 2006
Moda Technology Partners is a commercial software company whose primary focus is addressing the growing need for effective automation and efficient regulatory compliance within pharmaceutical manufacturing. Moda's software systems leverage mobile computing technology to help pharmaceutical clients increase operational efficiency, improve quality, and reduce manufacturing costs.

StreetLight Data

Series B in 2016
StreetLight Data brings mobility patterns to light for planners, modelers, and engineers by giving them on-demand access to the Big Data resources and processing software for transportation. Their online platform, StreetLight InSight lets its users turn anonymous location data from millions of mobile devices into customized, actionable analytics. It was founded in 2012 and is headquartered in San Francisco, California.

Earnest Research

Series A in 2014
Earnest Research is a data innovation company driven to change the way professionals understand consumer and business behavior. Working with world-class data partners, we transform raw data into a source for business and investment professionals to ask better questions so they can make better decisions.

Cyteir Therapeutics

Series C in 2021
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

NuMat Technologies, Inc.

Series B in 2018
NuMat Technologies, Inc., a technology company, engages in the design and integration of atomically engineered materials into gas delivery, separation, and purification systems enabled by metal-organic frameworks, a class of nanoporous materials that can be programmed to selectively interact with targeted gases and chemicals. The company’s portfolio includes ION-X, a solution for the sub-atmospheric storage and delivery of hazardous implant gases. It also offers a platform for product commercialization, pairing material discovery software with rapid prototyping and system integration. The company was founded in 2012 and is based in Skokie, Illinois.

Quantum Circuits, Inc.

Series A in 2017
Quantum Circuits, Inc. develops, manufactures, and sells quantum computers based on superconducting devices. The company was incorporated in 2015 and is based in New Haven, Connecticut.
Indico Data Solutions, INC. develops an enterprise artificial intelligence-based solution for unstructured content process automation. Its platform enables enterprises to create customized machine learning models using smaller data sets and machine learning tools. Indico Data Solutions, INC. was founded in 2013 and is based in Boston, Massachusetts.

Earnest Research

Series B in 2019
Earnest Research is a data innovation company driven to change the way professionals understand consumer and business behavior. Working with world-class data partners, we transform raw data into a source for business and investment professionals to ask better questions so they can make better decisions.

Menlo Security, Inc.

Series C in 2017
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

Kymeta Corporation

Series C in 2013
Kymeta is developing antennas for next generation satellite communications for mobile and fixed applications. Kymeta’s innovative antennas use metamaterials technology to dynamically steer the beam towards the satellite with no moving parts resulting in flat, thinner, lighter, more efficient and less expensive antennas. First to market will be a Portable Satellite Terminal- a laptop sized device with high speed internet connectivity and a built-in WiFi hotspot. Kymeta is also working on fixed antennas as well as antenna modules that can be incorporated as part of satellite terminals for any moving platform such as airplanes, trucks, trains, buses, automobiles or vessels.

FieldView Solutions

Venture Round in 2011
FieldView Solutions helps data center managers, IT and Facilities Management professionals make better use of their physical floor space, rack space, power and cooling by showing them real-time representations of all the critical systems in their data center. Their core platform, FieldView, a web-based enterprise solution, has been leveraged by many of the largest data centers in the US, Europe and Asia since 2006.

SevOne

Series A in 2007
Provides infrastructure performance monitoring solutions for customers worldwide

Pneuron

Series A in 2011
Pneuron overcomes the time, cost, and complexity challenges associated with traditional enterprise development, deployment and integration approaches. Using Pneuron’s Distributed Platform, organizations can leverage existing systems and infrastructure to connect data, applications, processes, and analytics without the need of intermediary databases, associated data integration costs or system replacement. In a single non-invasive “fabric” Pneuron allows the enterprise to manage the entire business solution lifecycle from a single screen – including development, deployment, integration, resiliency, availability and performance - freeing the enterprise to focus on realizing business value. The result is unprecedented productivity, engagement of business expertise, and reduced cost of success, inspiring new waves of innovation.

Corridor Pharmaceuticals

Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

HelloTeam

Seed Round in 2020
HelloTeam is a modern engagement and talent management platform, designed to increase employee engagement, impact retention and create data-driven people strategies backed by real-time instant insights and analytics. Our platform enables employees to be seen, heard and valued, leading to a more engaged, connected and inspired workforce.

Otonomy, Inc.

Series C in 2013
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.
BookKeeping Express combines technology and people to give small and medium businesses the full range of bookkeeping, management accounting, and financial reporting services that they can use to better understand and grow their businesses. As a national provider of complete financial transaction processing, including business bookkeeping, general ledger, payroll, bill pay, cash management, merchant services, and reporting, we have served the business community for more than 28 years. Between our experienced Team Center and our extended network of professionals, we are committed to bringing 21st century modernization to bookkeeping and small business processes.

Luxtera

Series A in 2002
Luxtera, Inc., designs and builds front panel and embedded optical modules based on its silicon photonics technology for data centers and mobile infrastructure. Its products include faceplate pluggable optical transceivers and embedded optical transceiver. Luxtera, Inc. was founded in 2001 and is based in Carlsbad, California. As of February 6, 2019, Luxtera, Inc. operates as a subsidiary of Cisco Systems, Inc.

Picwell

Series B in 2018
PICWELL INC. operates an online predictive recommendation engine that enables consumers to select their health plan. The company forecasts a consumer's future healthcare needs using lifestyle, behavioral, and financial data, as well as various health claims. It serves exchanges and marketplaces, benefit platforms, lead generators, agents and brokers, retail pharmacies, and employers. The company was incorporated in 2013 and is based in Philadelphia, Pennsylvania.

PsiKick

Series A in 2014
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-power circuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams. The company was founded on 2012 and is based in Santa Clara, California.

HardMetrics

Series A in 2006
HardMetrics Inc. provides on-demand enterprise business analytics and reporting solutions for call centre driven businesses. The company specializes in optimizing sales, service, and operations by transforming enterprise data into actionable information for effective measurement and precise decision making.

InstaMed

Venture Round in 2014
InstaMed powers a better healthcare payment experience on one platform that connects consumers, providers, and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, moving money, and healthcare data seamlessly, and improving consumer satisfaction. It was formed in 2004 and headquartered in Philadelphia, Pennsylvania.

DrayNow

Series A in 2018
DrayNow is the first real-time marketplace for matching intermodal freight and carriers. The company's intermodal marketplace uses technology to connect intermediaries to more carriers on short notice, maintain visibility of the shipment's location and status at all times, and helps truckers to compare rates, view load details, and select available loads in their area in real-time, enabling companies in the intermodal industry to operate with increased efficiency in order to maintain optimal levels of capacity, service, visibility, and profitability.

Clinipace

Series C in 2012
Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Circonus, Inc.

Series A in 2020
Circonus is a machine data intelligence and analytics platform for the world’s most demanding use cases. It collects, stores, manages, and analyzes IoT and IT Infrastructure data at unprecedented volume and frequency. The platform enables companies to optimize operations, gain valuable insights, and deliver user experiences with total confidence that they are getting accurate, real-time information. The company was founded in 2010 and is headquartered in Fulton, Maryland.

Homology Medicines, Inc.

Series B in 2017
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Aptinyx

Series A in 2016
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Immune Design

Series C in 2013
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Mirna Therapeutics

Series C in 2012
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Kymeta Corporation

Series D in 2016
Kymeta is developing antennas for next generation satellite communications for mobile and fixed applications. Kymeta’s innovative antennas use metamaterials technology to dynamically steer the beam towards the satellite with no moving parts resulting in flat, thinner, lighter, more efficient and less expensive antennas. First to market will be a Portable Satellite Terminal- a laptop sized device with high speed internet connectivity and a built-in WiFi hotspot. Kymeta is also working on fixed antennas as well as antenna modules that can be incorporated as part of satellite terminals for any moving platform such as airplanes, trucks, trains, buses, automobiles or vessels.

SolarBridge Technologies

Series D in 2012
SolarBridge Technologies, formerly SmartSpark Energy Systems, was founded in 2004 to commercialize power electronics technologies created at the University of Illinois. In early 2009, they launched a new corporate strategy to focus exclusively on the solar industry with microinverter and monitoring solutions. The company has a major research and development site in Champaign, Illinois and has recently expanded to include a new corporate headquarters in Austin, Texas. Led by industry veterans and academic professionals, their mission is to reduce the Levelized Cost of Energy (LCOE) for solar installations by dramatically improving reliability, increasing energy production, and simplifying installation.

CampaignerCRM

Convertible Note in 2009
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.

RedLasso

Venture Round in 2009
Redlasso is a web service that allows users to search TV and radio broadcasts, create clips and share them. On May 20, 2008, it was leaked that RedLasso had been [served](http://www.techcrunch.com/2008/05/20/bloggers-rejoice-customized-tv-clips-with-redlasso/) a Cease and Desist letter from a number of major media organizations. In response, the company [brought on](http://corp.redlasso.com/press/Redlasso-052908-01.pdf) Michael Jordan, former CEO of CBS and Westinghouse Corporation, as a senior advisor.

Melior Discovery

Series A in 2006
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Liquid Light Corporation

Series A in 2011
Liquid Light Corporation develops and licenses process technology to make chemicals from carbon dioxide (CO2). Its technology is centered on low-energy catalytic electrochemistry to convert CO2 to multi-carbon chemicals. The company is developing process for the production of ethylene glycol. Liquid Light Corporation was incorporated in 2008 and is based in Monmouth Junction, New Jersey. As of January 10, 2017, Liquid Light Corporation operates as a subsidiary of Avantium Technologies B.V..
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Halfpenny Technologies

Series A in 2010
Halfpenny Technologies, Inc. develops cloud-based healthcare interoperability solutions. It provides clinical data exchange solutions, orders management and computerized provider order entry solutions, business intelligence and notification solutions, and clinical data services. The company’s cloud-based solutions offers vendor-neutral infrastructure that supports care coordination, care management, regulatory requirements, and data analysis within and between healthcare organizations. It serves health plans, accountable care organizations, hospitals, radiology centers, pharmacies, commercial laboratories, population health, care coordination vendors, and HIEs in the United States. The company was founded in 2000 and is based in Blue Bell, Pennsylvania. As of June 14, 2019, Halfpenny Technologies, Inc. operates as a subsidiary of Accumen.

SevOne

Series A in 2009
Provides infrastructure performance monitoring solutions for customers worldwide

Neuros Medical

Series B in 2021
Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.

RackWare Incorporated

Series A in 2013
RackWare offers mobility to the data center to leverage private, public, or hybrid cloud environments. RackWare enables seamless transfer of those images to any other data center (physical or cloud) and deployment on any physical, virtual, or cloud platform. It was founded in 2009 and headquartered in Fremont, California.

BA Insight

Series A in 2010
BA Insight develops integrated search technologies that help organizations enhance Microsoft SharePoint® usage

E-scape Bio

Venture Round in 2020
E-Scape Bio, Inc., a biopharmaceutical company, discovers and develops small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. Its programs improve the lives of patients suffering from Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Skytree, Inc.

Series A in 2013
Skytree is a California-based software company that develops and publishes a machine learning platform for advanced analytics. The company offers a platform that gives organizations the power to discover analytic insights, predict future trends, make recommendations, and reveal untapped markets and customers. Backed by investments from US Venture Partners, Javelin Venture Partners, Samsung, UPS, and In-Q-Tel, Skytree is involved in enterprise-grade machine learning. The company was founded in 2012 by [Martin Hack](https://www.crunchbase.com/person/martin-hack) and [Alexander Gray](https://www.crunchbase.com/person/alexander-gray). It is headquartered in San Jose, C.A.

Q32 Bio

Series B in 2020
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Effector Therapeutics

Series A in 2013
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Immune Design

Series B in 2010
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

ReCode Therapeutics

Series A in 2020
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Medisix Therapeutics

Series A in 2018
Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

Full Measure Education

Series A in 2019
Full Measure Education is a Student Lifecycle and Retention Management company developing a student-facing mobile/social/web technology and human-powered retention services that keep students from dropping out of college. Full Measure Education’s cutting edge approach and technology design is the result of lessons learned by its senior management through 10,000,000 plus student help desk interactions at 850 plus colleges and universities. As a result, Full Measure Education has more post-secondary experience with which to deliver extraordinary outcomes in every major benchmark, including retention, enrollment growth, operational efficiencies, and financial aid utilization.

Translator LLC

Venture Round in 2016
Translator is an AI and human-supported chatbot technology that ensures employees get the support they need to navigate difficult conversations at work in real-time. Delivered via mobile phone, Translator delivers guided, narrative journeys designed to foster and measure soft skill development. The interactive user experience is designed to help users better understand their own identity and learn from diverse individuals and situations relevant to their industry or profession, i.e. healthcare or public services. The company was founded in 2016, based in New York City.

Virdante Pharmaceuticals

Series A in 2009
Virdante Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes drugs for autoimmune and inflammatory diseases. It offers antibody and Fc-fusion drugs to treat auto-immune diseases. The company was formerly known as Centaurus Pharmaceuticals and changed its name to Virdante Pharmaceuticals, Inc. in April, 2008. The company was founded in 2007 and is based in Cambridge, Massachusetts.

VividCortex

Series A in 2017
VividCortex, Inc. develops and delivers Software as a Service (SaaS) based MySQL monitoring and analysis tools. The company primarily focuses on tools for systems management. Its products enable customers to measure, analyze, and understand system behavior. VividCortex, Inc. was incorporated in 2012 and is based in Washington, District Of Columbia with additional offices in Arlington, Texas and Charlottesville, Virginia.

Tangent Medical Technologies

Seed Round in 2011
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Vor Biopharma

Series B in 2020
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receptos

Venture Round in 2012
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Receptos

Series B in 2013
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

InstaMed

Venture Round in 2010
InstaMed powers a better healthcare payment experience on one platform that connects consumers, providers, and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, moving money, and healthcare data seamlessly, and improving consumer satisfaction. It was formed in 2004 and headquartered in Philadelphia, Pennsylvania.

Cleave Biosciences

Series A in 2011
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Atsena Therapeutics

Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Ribon Therapeutics

Venture Round in 2015
Ribon Therapeutics, Inc. operates as biotechnology company, which develops therapeutics novel enzymes for cancer medicines. The company was incorporated in 2015 and is based in Lexington, Massachusetts.

Vector Launch, Inc.

Series A in 2017
Vector was founded by several members of the original SpaceX team and is a disruptive innovator that connects space startups with affordable and frequent launch and platforms to enable space capabilities at a speed and price point never before possible. Vector has a big vision to reshape the 400 billion dollar space market by combining dedicated low-cost micro satellite launch and software defined satellites (Galactic Sky) to dramatically increase access and speed to orbit.

Ambiq Micro, Inc.

Venture Round in 2018
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

Spero Therapeutics

Series B in 2016
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.

PsiKick

Series B in 2015
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-power circuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams. The company was founded on 2012 and is based in Santa Clara, California.

Blade Therapeutics, Inc.

Series A in 2015
Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Cardioxyl Pharmaceuticals

Series B in 2012
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.

Cyteir Therapeutics

Series B in 2019
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

HiveIO Inc

Series B in 2017
HiveIO Inc. provides public cloud solutions with the security control and governance of the private cloud for enterprises and SMB customers. It offers a cloud compute service that includes provisioning, lifecycle, security, and remote management. The company also offers HADOOP solution, virtual desktop solution, virtual server solution, connection broker, guest profile management, management center, remote management, connection broker API, remote management API, security APIs, user profile API, end-to-end lifecycle management, management portal, user behavior insights, high speed data bus, hypervisor, KPI, threshold modeling, forecasting engine, local storage acceleration, orchestration engine, and secure virtual switch, as well as provides VDI software on Lenovo servers. HiveIO Inc. was founded in 2015 and is based in Dover, Delaware.

Sidecar

Series A in 2014
Sidecar is an e-commerce marketing company that builds the advanced technology retailers need to optimize cross-channel online shopping campaigns. With a team of data science and e-commerce experts, our state-of-the-art machine learning engine, and a massive volume of data, Sidecar is the magic behind retail's most efficient and powerful online shopping campaigns.

Evolv Technology

Series A in 2013
Evolv Technologies, Inc. manufactures noninvasive body scanners for touchless security screening. It offers Evolv Express, a smart firearm and bomb detection system; Evolv Edge, a smart checkpoint system; and Evolv Pinpoint, a facial recognition system that identifies VIPs and persons of interest. The company’s products are used for employee screening, school safety, VIP screening, and visitor screening applications in public attractions, stadiums, entertainment venues, houses of worship, hotels, hospitals, and other places. Evolv Technologies, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Paracosm Inc.

Venture Round in 2015
Paracosm develops mobile reality capture, progress monitoring, and visualization solutions to help construction teams build better. With quick and easy scanning, job sites can be captured daily or weekly to gain powerful insights into projects and prevent rework. Their tools bring productivity for BIM/VDC to the next level, improve documentation, and make tracking construction progress easier than ever. Paracosm is a 3D mapping software company located in Gainesville, Florida. Their engineering team includes top computer vision engineers, parallel-processing devs, and 3D experts all striving to build the world’s best 3D mapping and visualization solutions.

ProtonMedia

Series B in 2011
ProtonMedia, Inc. provides e-learning solutions. The company develops ProtoSphere, a business collaboration software that allows organizations to create a 3D environment optimized for business applications, such as e-learning and virtual meetings, as well as virtual conference events, scientific research and development, and sales and manufacturing collaborations involving rich data visualization. It serves clients in pharmaceuticals, medical devices, financial services, and technology worldwide. ProtonMedia, Inc. was founded in 1998 and is based in Lansdale, Pennsylvania.

Enlibrium

Series A in 2015
Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.

InstaMed

Venture Round in 2012
InstaMed powers a better healthcare payment experience on one platform that connects consumers, providers, and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, moving money, and healthcare data seamlessly, and improving consumer satisfaction. It was formed in 2004 and headquartered in Philadelphia, Pennsylvania.

Clinipace

Series C in 2011
Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

Cleave Biosciences

Series C in 2019
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Cell Design Labs, Inc.

Venture Round in 2016
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability

Sera Prognostics

Series A in 2011
Sera Prognostics, Inc., a biotechnology company, develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. It focuses on addressing the economic and healthcare burden that premature birth places on infants, their families, and society. Sera Prognostics, Inc. was founded in 2008 and is based in Salt Lake City, Utah.

Iconic Therapeutics

Series C in 2016
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Merganser Biotech

Venture Round in 2016
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Sidecar

Series B in 2015
Sidecar is an e-commerce marketing company that builds the advanced technology retailers need to optimize cross-channel online shopping campaigns. With a team of data science and e-commerce experts, our state-of-the-art machine learning engine, and a massive volume of data, Sidecar is the magic behind retail's most efficient and powerful online shopping campaigns.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Immune Design

Series A in 2008
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Infinite Uptime

Series A in 2018
Infinite Uptime provides an IoT platform that automates predictive maintenance for industrial machines, with an initial focus on the manufacturing industry. Infinite Uptime provides an all-in-one industrial solution with hardware, cloud analytics, and control software to monitor equipment, diagnose problems, and drive smart decision making.

LunaPBC, Inc.

Venture Round in 2019
LunaPBC, Inc. develops a platform for health and DNA research. The company offers LunaDNA, a genomic and medical research knowledge database. Its platform allows individuals to share their health and DNA data for health research and discoveries. It caters to pharmaceutical, insurance, and healthcare information technology (IT) companies. LunaPBC, Inc. was formerly known as Luna DNA Inc. Luna DNA Inc. was incorporated in 2017 and is based in San Diego, California.

Pneuron

Series B in 2015
Pneuron overcomes the time, cost, and complexity challenges associated with traditional enterprise development, deployment and integration approaches. Using Pneuron’s Distributed Platform, organizations can leverage existing systems and infrastructure to connect data, applications, processes, and analytics without the need of intermediary databases, associated data integration costs or system replacement. In a single non-invasive “fabric” Pneuron allows the enterprise to manage the entire business solution lifecycle from a single screen – including development, deployment, integration, resiliency, availability and performance - freeing the enterprise to focus on realizing business value. The result is unprecedented productivity, engagement of business expertise, and reduced cost of success, inspiring new waves of innovation.

Algorithmia, Inc.

Seed Round in 2014
Algorithmia, Inc. provides the infrastructure that enables algorithm developers to explore, create, and share algorithms as Web services. The company helps its clients deploy models into production by creating a versioned, scalable API (application program interface) endpoint any application or model can call. The company's product helps clients work on Tensorflow, PyTorch, Scikit-learn, and MXNet. Algorithmia, Inc. was founded in 2013 and is based in Seattle, Washington.

Aptinyx

Series B in 2017
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Carnegie Speech

Series A in 2007
Carnegie Speech Company, Inc., a speech assessment and tutoring software company, provides speech training technology to help to speak English clearly. It offers Carnegie Speech Assessment, which rate the proficiency of spoken English; Native Accent, which teach to pronounce English clearly; and YOUTH Database, a set of recordings of children reading words, phrases, and sentences in English. The company serves BPO and education markets. Carnegie Speech Company, Inc. was founded in 2001 and is based in Pittsburgh, Pennsylvania.

Picwell

Series A in 2015
PICWELL INC. operates an online predictive recommendation engine that enables consumers to select their health plan. The company forecasts a consumer's future healthcare needs using lifestyle, behavioral, and financial data, as well as various health claims. It serves exchanges and marketplaces, benefit platforms, lead generators, agents and brokers, retail pharmacies, and employers. The company was incorporated in 2013 and is based in Philadelphia, Pennsylvania.

Menlo Security, Inc.

Series B in 2015
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

Aerovate Therapeutics

Series A in 2020
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

CXOWARE

Series B in 2019
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.

MarginEdge Co.

Series A in 2020
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.

Beam Therapeutics Inc.

Series A in 2018
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.

Body Labs

Series A in 2015
Body Labs is a horizontal solution provider of human-aware AI that understands the way we move and how we’re shaped to make our world more personal. The company is comprised of the best in artificial intelligence, computer vision, and body modeling. It aims to deliver human-aware AI as the next digital platform to empower the capture and use of 3D body motion and shape for numerous industries. It was founded in 2013 and is headquartered in New York, New York.

Noodle Partners

Seed Round in 2016
Noodle Partners creates innovative online and hybrid programs while improving traditional classroom models. Noodle Partners has the capability to work with universities on every aspect of building a certificate or degree program that they choose—marketing, student recruitment, enrollment, curriculum design, student engagement, support services, graduate placement, and alumni engagement—and provides a high level of fit and finish.

Ambiq Micro, Inc.

Series C in 2014
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

Merganser Biotech

Series A in 2015
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

IonQ, Inc.

Series A in 2017
IonQ, Inc. develops general-purpose quantum information computers. The company combines physical performance, qubit replication, optical networkability, and optimized algorithms to create a quantum computer. Its product quantum computing represents a radical departure from classical computing and overcomes limitations, such as superposition and entanglement that emerge at atomic scale. The company was incorporated in 2015 and is based in College Park, Maryland.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Gevo, Inc.

Venture Round in 2009
Gevo, Inc. operates as a renewable fuels company. It commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. The company uses low-carbon renewable-resource-based carbohydrates as raw materials and is developing renewable electricity and renewable natural gas for use in production processes. It products also include renewable biodiesel, isooctane, isobutanol, sustainable aviation fuel, isobutylene, ethanol, and animal feed. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Gevo, Inc.

Series D in 2010
Gevo, Inc. operates as a renewable fuels company. It commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. The company uses low-carbon renewable-resource-based carbohydrates as raw materials and is developing renewable electricity and renewable natural gas for use in production processes. It products also include renewable biodiesel, isooctane, isobutanol, sustainable aviation fuel, isobutylene, ethanol, and animal feed. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Millendo Therapeutics, Inc.

Venture Round in 2018
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

KenSci Inc.

Series B in 2019
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.

Galactic Fog IP, Inc.

Venture Round in 2016
Galactic Fog IP, Inc. develops a cloud-native management platform for companies to build future-proofed applications. The company offers lambda application server, a lambda service that runs on .Net, Javascript, Java, Scala, Ruby, and Python lambdas to integrate with other systems, including message queuing or notification systems. It also provides container management solutions; policy engine that allows users to control various aspects of lambda and container deployment and usage; and integration services. The company was incorporated in 2015 and is based in South Orange, New Jersey.

ExecOnline, Inc.

Series A in 2014
ExecOnline, Inc. provides a learning platform for business executives. Its Executive Engagement Platform combines enterprise reporting and assessment solutions with an engaging and interactive experience user for individual executive learners. The company also provides online business education programs to business schools and corporate sectors. ExecOnline, Inc. was incorporated in 2012 and is based in New York, New York.

SolarBridge Technologies

Series C in 2011
SolarBridge Technologies, formerly SmartSpark Energy Systems, was founded in 2004 to commercialize power electronics technologies created at the University of Illinois. In early 2009, they launched a new corporate strategy to focus exclusively on the solar industry with microinverter and monitoring solutions. The company has a major research and development site in Champaign, Illinois and has recently expanded to include a new corporate headquarters in Austin, Texas. Led by industry veterans and academic professionals, their mission is to reduce the Levelized Cost of Energy (LCOE) for solar installations by dramatically improving reliability, increasing energy production, and simplifying installation.

Iconic Therapeutics

Series C in 2016
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Clinipace

Venture Round in 2018
Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

Embodied, Inc.

Series A in 2018
Embodied is an AI company that develops state-of-the-art companion robots that aim to revolutionize care and wellness, enhancing the quality of life for individuals and families. They are combining 14 years of research in socially assistive robotics from the University of Southern California with 15 years of experience with commercialization of consumer robotics from iRobot, and decades of animation and storytelling to build life-like, interactive robots to serve as motivators, coaches, and companions that help and empower people to be better at helping themselves.

MC10, Inc.

Series C in 2012
MC10, Inc. develops and sells wearable medical sensors for collecting medical grade, clinical quality bio-metric, and physiological data in a clinical trial setting. The company’s products include BioStamp nPoint, which collects and processes raw data into recognizable clinical metrics including vital signs, activity and posture classification, and sleep metrics; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, a cardiac monitoring and electrocardiographs (ECG) recording solution; and BioStampMD, a wearable sensor conforming to the human body to collect objective and patient-reported subjective data. It sells its products online. The company was founded in 2008 and is based in Lexington, Massachusetts.

Avid Radiopharmaceuticals

Series A in 2006
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Ceptaris Therapeutics

Series D in 2012
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

PMV Pharmaceutcals

Series B in 2017
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Phone2Action

Venture Round in 2016
Phone2Action is the market-leading advocacy and communications platform which helps organizations engage with supporters, employees, customers and other stakeholders and empower them to communicate with policymakers at local, state, national and international levels via email, Twitter, Facebook and patch-through calling. Our technology has assisted in influencing policy decisions for over 200 clients, ranging from Fortune 100 corporations to the largest associations and non-profits. Named one of DC Inno’s 2016 50 on Fire, CB Insights’ 2016 list of 21 Nonprofit and Charity Tech Startups to Watch, and one of Trending 40’s 2016 Red Hot Companies, Phone2Action is poised for explosive growth.

KenSci Inc.

Series A in 2017
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.

StreetLight Data

Series C in 2018
StreetLight Data brings mobility patterns to light for planners, modelers, and engineers by giving them on-demand access to the Big Data resources and processing software for transportation. Their online platform, StreetLight InSight lets its users turn anonymous location data from millions of mobile devices into customized, actionable analytics. It was founded in 2012 and is headquartered in San Francisco, California.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Paracosm Inc.

Seed Round in 2014
Paracosm develops mobile reality capture, progress monitoring, and visualization solutions to help construction teams build better. With quick and easy scanning, job sites can be captured daily or weekly to gain powerful insights into projects and prevent rework. Their tools bring productivity for BIM/VDC to the next level, improve documentation, and make tracking construction progress easier than ever. Paracosm is a 3D mapping software company located in Gainesville, Florida. Their engineering team includes top computer vision engineers, parallel-processing devs, and 3D experts all striving to build the world’s best 3D mapping and visualization solutions.

MarginEdge Co.

Seed Round in 2019
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.

Cyteir Therapeutics

Series B in 2018
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

Malbek

Seed Round in 2020
Malbek is an AI platform that provides enterprise contract lifecycle management from a request, redlining, signature, and commitment tracking. It provides an innovative quote and contract lifecycle management solution that is laser-focused on accelerating contract cycle time, improving efficiency, and increasing contract visibility. With user experience as simple as using an ATM, its solution provides end-users as well as application admins a simple consumer-grade user interface with all configurable, no code-customization, capabilities.
Palladio Biosciences, Inc., a biotechnology company, that develops transformative medicines for orphan diseases of the kidney. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. Palladio Biosciences, Inc. was founded in 2015 and is based in Horsham, Pennsylvania.

GoCanvas

Series D in 2016
GoCanvas is a mobile platform that makes it simple for any business to automate how work is done, replacing outdated processes and expensive paperwork. The GoCanvas App works on all smartphones and tablets, helping companies easily collect information across their organization, share it instantly with others, and gain real-time insights on their business operations. It was founded in 2008 and headquartered in Reston, Virginia.

redIQ

Venture Round in 2015
redIQ transforms static property data into actionable intelligence. Using sophisticated data parsing and processing tools, we allow clients to quickly and accurately extract the vast troves of rent roll and operating data from the files they receive in seconds rather than hours. This data is immediately aggregated and analyzed using cutting-edge data visualization tools to provide unique insights. Clients can then share controlled subsets of that information in a dynamic, easy-to-consume format. It was founded in 2012 and is headquartered in New York, New York.

SiFive, Inc.

Series B in 2017
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and more affordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small.

Mirna Therapeutics

Series D in 2015
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

CounterFlow AI, Inc.

Seed Round in 2018
Threat hunting is the emerging modis operandi in cybersecurity. Industry Experts concede that eliminating threats entirely is impossible and breaches are inevitable. Defense-in-depth systems like firewalls and intrusion detection are necessary; but, not sufficient. As a result, security analysts are adopting the adage, “the best defense is a good offense”, by shifting from a passive, fortress mentality to an active, hunting mindset.

Corelight, Inc.

Series A in 2017
Corelight, Inc. provides network visibility solutions for information security professionals. It offers Corelight sensors; Corelight fleet manager; software products; and solutions to secure networks for enterprises, government, and higher education sectors. The company also provides open-source Bro, an open source network analysis framework that generates actionable, real-time data for various security teams worldwide. Corelight, Inc. was founded in 2013 and is based in San Francisco, California. It has additional offices in San Francisco and Santa Clara, California; and Columbus, Ohio.

E-scape Bio

Series A in 2017
E-Scape Bio, Inc., a biopharmaceutical company, discovers and develops small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. Its programs improve the lives of patients suffering from Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Perceptive Automata, Inc.

Seed Round in 2017
Perceptive Automata, Inc. develops machine learning and computer vision solutions. Its solutions are used in the automated vehicles to understand what people might do next, so solutions can navigate around humans, including pedestrians, cyclists, and other drivers. The company was incorporated in 2014 and is based in Somerville, Massachusetts.

Infinio

Series B in 2013
Infinio addresses the most expensive bottleneck in virtual environments: storage performance. Data center administrators buy more storage hardware when what they really want is better storage performance. Infinio offers a software-only solution instead. Infinio has strong financial backing from tier-one venture capitalists including Highland Capital Partners, Bessemer Venture Partners, Lightspeed Venture Partners and Osage University Partners.

Jibo

Seed Round in 2014
Founded in 2012, Jibo is widely known for creating the eponymous robot, Jibo: the first social robot for the home. Jibo is built to interact and communicate with the people around him, and he uses advanced Natural Language Understanding (NLU) along with speech and facial recognition to forge relationships with his family. Jibo, Inc. officially launched Jibo to the public in 2017 after nearly three years of intensive development and optimization. The company is privately held and headquartered in Boston.

Algorithmia, Inc.

Series A in 2017
Algorithmia, Inc. provides the infrastructure that enables algorithm developers to explore, create, and share algorithms as Web services. The company helps its clients deploy models into production by creating a versioned, scalable API (application program interface) endpoint any application or model can call. The company's product helps clients work on Tensorflow, PyTorch, Scikit-learn, and MXNet. Algorithmia, Inc. was founded in 2013 and is based in Seattle, Washington.

Lastline, Inc.

Series C in 2017
Lastline provides a malware protection platform to detect and stop advanced persistent threats, zero-day exploits, and evasive malware. The company was founded in 2011 by world-renowned security researchers and creators of Anubis and Wepawet – malware analysis tools used by thousands of security vendors, enterprises, and government agencies worldwide. The company is headquartered in Redwood City, California, with offices in North America, Europe, and the Asia Pacific.

Ribon Therapeutics

Series B in 2019
Ribon Therapeutics, Inc. operates as biotechnology company, which develops therapeutics novel enzymes for cancer medicines. The company was incorporated in 2015 and is based in Lexington, Massachusetts.

Gevo, Inc.

Series A in 2005
Gevo, Inc. operates as a renewable fuels company. It commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. The company uses low-carbon renewable-resource-based carbohydrates as raw materials and is developing renewable electricity and renewable natural gas for use in production processes. It products also include renewable biodiesel, isooctane, isobutanol, sustainable aviation fuel, isobutylene, ethanol, and animal feed. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

PreparedHealth

Series A in 2021
Dina Care is a provider of health plans, patients, and caregivers to produce great patient outcomes. The company connects personal caregivers and care providers and enables payers to keep their members healthier, safer, and happier at home. With Dina, everyone stays connected in real-time, receiving care updates as they happen, improving the odds a patient's in-home care will be successful. It creates a virtual experience for the entire healthcare team so they can communicate with each other and help patients and families stay connected even though they may not physically be under the same roof. Dina Care enabling consumers, health plans and ACOs to explore, learn, and engage with the rapidly growing number of services that keep people happy and healthy in their homes. The platform helps professional and family caregivers capture rich and timely data from the home, using AI technology to identify unmet needs, and recommend evidence-based interventions. Dina Care was founded in 2015 and is headquartered in Chicago, Illinois, USA.

Avid Radiopharmaceuticals

Series D in 2009
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

IonQ, Inc.

Series B in 2019
IonQ, Inc. develops general-purpose quantum information computers. The company combines physical performance, qubit replication, optical networkability, and optimized algorithms to create a quantum computer. Its product quantum computing represents a radical departure from classical computing and overcomes limitations, such as superposition and entanglement that emerge at atomic scale. The company was incorporated in 2015 and is based in College Park, Maryland.

Indico Data Solutions, INC.

Seed Round in 2018
Indico Data Solutions, INC. develops an enterprise artificial intelligence-based solution for unstructured content process automation. Its platform enables enterprises to create customized machine learning models using smaller data sets and machine learning tools. Indico Data Solutions, INC. was founded in 2013 and is based in Boston, Massachusetts.

Katabat

Series A in 2009
Katabat™ enables digital transformation with complete visibility across the consumer lifecycle. Experience our unified platform that increases customer satisfaction and retention, at a lower cost. Whether you are a servicer, lender, retailer, or utility, our SaaS solutions create an outstanding on-demand experience while driving security, compliance, and revenue. Katabat was founded by financial and technology industry experts, so we fully understand your security and compliance needs. Data security is part of our culture, and you can see that in our platform’s uncompromising security standards. Katabat™ is a PCI Level 1 Service Provider and your data is encrypted using the most secure F5 firewalls. https://katabat.com/our-story/

LunaDNA

Venture Round in 2019
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

Kura Oncology, Inc.

Venture Round in 2015
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Skytree, Inc.

Seed Round in 2012
Skytree is a California-based software company that develops and publishes a machine learning platform for advanced analytics. The company offers a platform that gives organizations the power to discover analytic insights, predict future trends, make recommendations, and reveal untapped markets and customers. Backed by investments from US Venture Partners, Javelin Venture Partners, Samsung, UPS, and In-Q-Tel, Skytree is involved in enterprise-grade machine learning. The company was founded in 2012 by [Martin Hack](https://www.crunchbase.com/person/martin-hack) and [Alexander Gray](https://www.crunchbase.com/person/alexander-gray). It is headquartered in San Jose, C.A.

SiFive, Inc.

Series D in 2019
SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and more affordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small.

Brazen Technologies, Inc.

Series B in 2016
Brazen Technologies, Inc. design and develops chat-based recruiting software. The company offers live chat, scheduled chat, chat events, and Artificial Intelligence-powered chatbots. It also provides a javascript-based career site and job requisition plugins. Brazen Technologies, Inc. was formerly known as Brazen Careerist, Inc. and change its name to Brazen Technologies, Inc. in February 2010. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Otonomy, Inc.

Series D in 2014
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Ambiq Micro, Inc.

Series C in 2016
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

CXOWARE

Series A in 2017
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.

Artizan Biosciences

Series A in 2021
Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

Brazen Technologies, Inc.

Series B in 2015
Brazen Technologies, Inc. design and develops chat-based recruiting software. The company offers live chat, scheduled chat, chat events, and Artificial Intelligence-powered chatbots. It also provides a javascript-based career site and job requisition plugins. Brazen Technologies, Inc. was formerly known as Brazen Careerist, Inc. and change its name to Brazen Technologies, Inc. in February 2010. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Menlo Security, Inc.

Series D in 2019
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, Neuberger Berman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California.

Selecta Biosciences

Series E in 2015
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

OpsDataStore

Series A in 2015
OpsDataStore, provides the first ever solution to online service quality issues by combining a low latency real time scalable big data back end with partner ecosystem of complementary management software vendors. This ecosystem approach gives customers the ability to choose best of breed vendors and achieve data integration through OpsDataStore. This allows customers to improve revenue, reliability, reputation and customer retention. The company was incorporated in 2015 and is based in Johns Creek, Georgia.
Capella Bioscience Limited engages in the discovery and development of monoclonal antibodies (mAbs). It focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics for oncology, autoimmune, and other diseases independently, as well in collaboration with biotechnology and academic partners. The company was founded in 2014 and is based in London, United Kingdom.

Carnegie Speech

Series B in 2012
Carnegie Speech Company, Inc., a speech assessment and tutoring software company, provides speech training technology to help to speak English clearly. It offers Carnegie Speech Assessment, which rate the proficiency of spoken English; Native Accent, which teach to pronounce English clearly; and YOUTH Database, a set of recordings of children reading words, phrases, and sentences in English. The company serves BPO and education markets. Carnegie Speech Company, Inc. was founded in 2001 and is based in Pittsburgh, Pennsylvania.

StreetLight Data

Series D in 2020
StreetLight Data brings mobility patterns to light for planners, modelers, and engineers by giving them on-demand access to the Big Data resources and processing software for transportation. Their online platform, StreetLight InSight lets its users turn anonymous location data from millions of mobile devices into customized, actionable analytics. It was founded in 2012 and is headquartered in San Francisco, California.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Voxel8

Series A in 2015
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.

Neuros Medical

Series A in 2017
Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.

ExecOnline, Inc.

Series C in 2018
ExecOnline, Inc. provides a learning platform for business executives. Its Executive Engagement Platform combines enterprise reporting and assessment solutions with an engaging and interactive experience user for individual executive learners. The company also provides online business education programs to business schools and corporate sectors. ExecOnline, Inc. was incorporated in 2012 and is based in New York, New York.

GoCanvas

Series C in 2013
GoCanvas is a mobile platform that makes it simple for any business to automate how work is done, replacing outdated processes and expensive paperwork. The GoCanvas App works on all smartphones and tablets, helping companies easily collect information across their organization, share it instantly with others, and gain real-time insights on their business operations. It was founded in 2008 and headquartered in Reston, Virginia.

PMV Pharmaceutcals

Series A in 2014
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Corridor Pharmaceuticals

Series A in 2009
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Seismos

Venture Round in 2019
Seismos, the K-wave Company™, is a data analytics company for production optimization providing proprietary solutions enabling real-time, underground fluid flow monitoring, inside the reservoir, during production. Monitoring fluid movement with conventional seismic technologies requires months for data acquisition and processing, disrupts production and costs millions. Seismos breaks this paradigm and solves all problems associated with conventional methods by providing real-time information, at a fraction of the cost, through its proprietary, cloud-based K-wave technology that is non-invasive to production and to surface operations.

Aerie Pharmaceuticals

Series B in 2011
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.